Biohaven (BHVN) is down -17.0%, or -$3.35 to $16.31.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven Ltd.’s Resilience and Strategic Growth Potential Amidst Regulatory Challenges
- Biohaven’s Troriluzole PDUFA Date Extended by FDA
- Biohaven Ltd. Receives Buy Rating Amid Promising FDA Progress and Strong Financial Position
- Closing Bell Movers: Foot Locker up nearly 70% on Dick’s buyout
- FDA extends PDUFA for Biohaven’s Troriluzole new drug application